PMVP
Income statement / Annual
Last year (2025), PMV Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, PMV Pharmaceuticals Inc's net income was -$77.74 M.
See PMV Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$133.00 K
|
$1.14 M
|
$1.26 M
|
$650.00 K
|
$1.28 M
|
$318.00 K
|
$388.00 K
|
$338.00 K
|
| Gross Profit |
-$133.00 K
|
-$1.14 M
|
-$1.26 M
|
-$650.00 K
|
-$1.28 M
|
-$318.00 K
|
-$388.00 K
|
-$338.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$69.88 M
|
$57.38 M
|
$54.63 M
|
$51.67 M
|
$36.19 M
|
$23.62 M
|
$20.76 M
|
$13.85 M
|
| General & Administrative Expenses |
$16.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.04 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.33 M
|
$26.92 M
|
$24.25 M
|
$24.72 M
|
$20.83 M
|
$11.01 M
|
$5.49 M
|
$5.04 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.00 K
|
| Operating Expenses |
$86.21 M
|
$84.30 M
|
$78.88 M
|
$76.39 M
|
$57.01 M
|
$34.62 M
|
$26.25 M
|
$18.89 M
|
| Cost And Expenses |
$86.21 M
|
$85.45 M
|
$80.13 M
|
$77.04 M
|
$58.29 M
|
$34.94 M
|
$26.64 M
|
$18.89 M
|
| Interest Income |
$6.34 M
|
$10.66 M
|
$11.17 M
|
$3.63 M
|
$449.00 K
|
$651.00 K
|
$1.30 M
|
$1.34 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$133.00 K
|
$1.14 M
|
$1.26 M
|
$650.00 K
|
$1.28 M
|
$318.00 K
|
$388.00 K
|
$338.00 K
|
| EBITDA |
-$86.21 M |
-$73.67 M |
-$67.70 M |
-$72.68 M |
-$56.54 M |
-$34.12 M |
-$24.96 M |
-$18.55 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.29 M
|
$10.64 M
|
$11.17 M
|
$3.71 M
|
$470.00 K
|
$508.00 K
|
$1.29 M
|
$1.36 M
|
| Income Before Tax |
-$79.91 M
|
-$74.81 M
|
-$68.96 M
|
-$73.33 M
|
-$57.82 M
|
-$34.43 M
|
-$25.34 M
|
-$17.54 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.17 M
|
-$16.10 M
|
$2.00 K
|
-$9.00 K
|
$23.00 K
|
$6.00 K
|
$8.00 K
|
$3.00 K
|
| Net Income |
-$77.74 M
|
-$58.71 M
|
-$68.96 M
|
-$73.32 M
|
-$57.85 M
|
-$34.44 M
|
-$25.35 M
|
-$17.54 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.48 |
-1.1382 |
-1.44 |
-1.61 |
-1.28 |
-2.4 |
-0.59 |
-5.8 |
| EPS Diluted |
-1.48 |
-1.1382 |
-1.44 |
-1.61 |
-1.28 |
-2.4 |
-0.59 |
-5.8 |
| Weighted Average Shares Out |
$52.54 M
|
$51.58 M
|
$48.01 M
|
$45.59 M
|
$45.14 M
|
$44.78 M
|
$43.00 M
|
$3.02 M
|
| Weighted Average Shares Out Diluted |
$52.54 M
|
$51.58 M
|
$48.01 M
|
$45.59 M
|
$45.14 M
|
$44.78 M
|
$43.00 M
|
$3.02 M
|
| Link |
|
|
|
|
|
|
|
|
